V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330010633 | 330005338 | 1.68 | 16.6 | Palliative (P) | 2015-11-30 | 2015-11-30 | VINCRISTINE | null | N | 330019627 | DHAP |
| 330010634 | 330005339 | 0 | 46.05 | Disease modification (D) | 2017-12-21 | 2018-01-07 | Triple Intrathecal | 02 | N | 330019637 | BORTEZOMIB |
| 330010635 | 330005340 | 1.53 | 63.2 | Palliative (P) | 2015-11-26 | 2015-11-27 | AML 19 TRIAL | N | N | 330019639 | CAPECITABINE + VINORELBINE |
| 330010636 | 330005342 | 1.76 | 130.1 | Neo-adjuvant (N) | 2017-11-24 | 2018-03-31 | AML17 TRIAL | 01 | N | 330019654 | DOXORUBICIN + IFOSFAMIDE |
| 330010637 | 330005346 | null | 7.7 | Curative (C) | 2013-12-06 | 2014-01-14 | Vincristine (weekly) | Y | null | 330019674 | FCR |
| 330010638 | 330005348 | null | 63 | Curative (C) | 2014-01-08 | 2015-05-13 | FCR Oral - Cycle 1 | null | N | 330019675 | CAPECITABINE + OXALIPLATIN |
| 330010639 | 330005350 | 1.53 | 59.9 | Curative (C) | null | 2017-02-16 | CYCLOPHOSPHAMIDE | null | N | 330019675 | UKALL XII |
| 330010641 | 330005356 | 1.65 | 53 | Curative (C) | 2015-03-03 | 2015-03-09 | CLADRIBINE | Y | N | 330019708 | FLUDARABINE + MELPHALAN |
| 330010642 | 330005359 | 1.82 | null | Curative (C) | null | 2015-09-18 | Carboplatin + Thiotepa + Topotecan | null | N | 330019771 | CISPLATIN + EPIRUBICIN |
| 330010643 | 330005363 | 1.78 | 75.7 | Curative (C) | 2013-06-08 | 2013-07-20 | BUSULFAN + MELPHALAN | N | null | 330019784 | UKALL60+ |
| 330010644 | 330008926 | null | 60 | Adjuvant (A) | 2017-07-28 | 2017-09-13 | Capecitabine 42days + RT | N | null | 330019806 | EDP + MITOTANE |
| 330010645 | 330005369 | 1.49 | null | Curative (C) | null | 2015-02-12 | Cisplatin + Gemcitabine (D 1 & 8) | null | N | 330019807 | CLADRIBINE |
| 330010647 | 330005374 | null | 89.15 | Curative (C) | 2016-04-25 | 2016-04-27 | BORTEZOMIB + RITUXIMAB | N | N | 330019900 | BENDAMUSTINE |
| 330010648 | 330005376 | 1.4 | null | Neo-adjuvant (N) | null | 2014-04-10 | Cyclophosphamide + Vincristine | null | null | 330019906 | PERTUZUMAB + TRASTUZUMAB |
| 330010649 | 330008930 | 1.63 | null | Adjuvant (A) | 2013-11-09 | 2013-11-09 | TRASTUZUMAB | N | N | 330019921 | CAP |
| 330010650 | 330011903 | 1.62 | 53.1 | Neo-adjuvant (N) | 2015-08-25 | 2015-09-09 | Bortezomib +/- Dexamethasone | Y | N | 330019924 | PEMBROLIZUMAB |
| 330010651 | 330012512 | 1.04 | null | Curative (C) | 2017-08-08 | 2017-08-16 | Capecitabine (14 days)+Carboplatin | Y | N | 330019928 | UKALL60+ |
| 330010653 | 330005386 | null | 50.4 | Curative (C) | 2014-01-07 | 2014-01-07 | CETUXIMAB + CISPLATIN + FU | 02 | N | 330019979 | CARBOPLATIN + CETUXIMAB + FU |
| 330010654 | 330011904 | 1.69 | 63.9 | Curative (C) | null | 2016-03-27 | CYTARABINE | Y | Y | 330020045 | CHLORAMBUCIL + RITUXIMAB |
| 330010655 | 330008937 | null | 77.1 | Palliative (P) | 2015-09-02 | 2015-09-02 | Bevacizumab 5mg/kg | 2 | N | 330020045 | MITOTANE |
| 330010657 | 330013077 | null | 68 | Curative (C) | null | 2018-02-15 | Ifosfamide + Liposomal Doxorubicin | null | Y | 330020060 | ALDESLEUKIN |
| 330010658 | 330005395 | 1.66 | 56.1 | Palliative (P) | 2015-10-14 | 2015-10-14 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 2 | N | 330020121 | UKALL 2011 |
| 330010659 | 330005398 | 1.74 | 50.7 | Disease modification (D) | 2016-11-25 | 2016-12-06 | Clofarabine + Cytarabine | 02 | N | 330020131 | CAP |
| 330010660 | 330005399 | 1.85 | null | Not known (9) | 2015-01-22 | 2015-01-26 | PEI | N | N | 330020134 | IVA |
| 330010661 | 330005400 | 1.84 | 45.85 | Neo-adjuvant (N) | 2016-11-15 | 2017-02-12 | Cyclophosphamide + Vincristine | Y | N | 330020140 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 330010662 | 330005402 | 1.7 | 8.8 | Curative (C) | 2017-06-29 | 2018-01-02 | MaxiCHOP (Cycle 1) | 01 | N | 330020153 | DOXORUBICIN + METHOTREXATE |
| 330010663 | 330008944 | null | 115.7 | Neo-adjuvant (N) | 2014-10-27 | 2014-11-04 | FLA | 02 | null | 330020179 | EDP |
| 330010664 | 330005407 | 1.72 | 121.6 | Neo-adjuvant (N) | 2015-04-12 | 2015-04-15 | PEMBROLIZUMAB | 02 | null | 330020179 | OFATUMUMAB |
| 330010665 | 330008947 | 1.82 | 74.6 | Adjuvant (A) | 2015-10-27 | 2015-10-27 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | 02 | N | 330020208 | DOXORUBICIN + METHOTREXATE |
| 330010666 | 330005412 | 1.6 | null | Neo-adjuvant (N) | null | 2016-05-01 | EC | N | null | 330020223 | BORTEZOMIB + THALIDOMIDE |
| 330010668 | 330011907 | 0 | 13.7 | Curative (C) | 2015-11-13 | 2015-11-13 | EMA | 2 | N | 330020236 | ARSENIC TRIOXIDE |
| 330010669 | 330011907 | null | null | Palliative (P) | 2015-06-22 | 2015-06-25 | CISPLATIN + GEMCITABINE + RITUXIMAB | N | null | 330020236 | AML19 TRIAL |
| 330010671 | 330008953 | 1.32 | 61 | Palliative (P) | 2013-11-07 | 2013-11-13 | R Chlorambucil | N | Y | 330020277 | CHOP R + BORTEZOMIB |
| 330010672 | 330005420 | 1.81 | null | Palliative (P) | 2016-06-23 | 2017-01-17 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | 330020280 | BEP |
| 330010674 | 330005423 | 0 | 38.4 | Curative (C) | 2017-10-15 | 2018-02-08 | CISPLATIN + EPIRUBICIN | y | N | 330020306 | CARBOPLATIN + VINCRISTINE |
| 330010675 | 330005425 | 1.71 | 88.2 | null | 2017-03-08 | 2017-03-10 | Cladribine (subcut) 5 days | 01 | N | 330020332 | ABVD |
| 330010676 | 330005427 | 1.75 | 74.6 | Palliative (P) | 2017-05-21 | 2017-05-21 | Alemtuzumab + Cyclophos TBI Allo | 02 | N | 330020346 | DOXORUBICIN + IFOSFAMIDE |
| 330010677 | 330008960 | 1.71 | 22 | Neo-adjuvant (N) | null | 2018-04-14 | CYCLOPHOSPHAMIDE | N | N | 330020348 | ATG + BUSULFAN + FLUDARABINE |
| 330010678 | 330005428 | 0 | null | Curative (C) | 2015-09-30 | 2015-10-07 | FMD Oral | 02 | Y | 330020376 | PONATINIB |
| 330010679 | 330008962 | 1.73 | 60 | Curative (C) | null | 2014-08-01 | Cyclophosphamide + Vincristine | null | N | 330020405 | CISPLATIN + GEMCITABINE |
| 330010682 | 330005433 | 0 | 87.8 | Palliative (P) | 2018-12-24 | 2018-12-28 | Bendamustine +/- Prednisolone | Y | N | 330020417 | CARBOPLATIN + DOCETAXEL |
| 330010683 | 330005435 | 1.64 | 90.1 | Curative (C) | 2015-09-26 | 2015-10-02 | Doxorubicin + Gemcitabine | N | null | 330020420 | IVA |
| 330010684 | 330005437 | 1.7 | 28.4 | Adjuvant (A) | 2014-08-31 | 2014-09-04 | EMA | N | N | 330020423 | DOXORUBICIN + IFOSFAMIDE |
| 330010685 | 330008966 | 1.58 | 98.1 | Curative (C) | 2018-03-02 | 2018-03-05 | CAP | 01 | N | 330020433 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330010686 | 330005444 | null | 14.9 | Palliative (P) | 2017-09-14 | 2017-09-17 | CNS HGG Bevacizumab + Irinotecan | N | N | 330020457 | IBRUTINIB |
| 330010687 | 330012859 | 1.79 | 50.7 | Palliative (P) | 2014-04-17 | 2014-05-15 | IBRUTINIB | N | N | 330020482 | CAP |
| 330010688 | 330005447 | 1.72 | 95.2 | Curative (C) | 2018-08-26 | 2018-08-26 | BUSULFAN + MELPHALAN | 02 | N | 330020501 | CARBOPLATIN + DOCETAXEL |
| 330010689 | 330005448 | 1.55 | 99.9 | Palliative (P) | 2016-10-29 | 2017-05-22 | CAPECITABINE + CARBOPLATIN + Cetuximab | Y | N | 330020501 | AML19 TRIAL |
| 330010690 | 330005451 | null | 98.4 | Neo-adjuvant (N) | 2013-03-08 | 2013-07-06 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 2 | N | 330020525 | CLADRIBINE |
| 330010691 | 330005452 | null | 22.2 | Palliative (P) | null | 2015-10-19 | CARBOPLATIN + Cetuximab + FLUOROURACIL | null | null | 330020527 | CLOFARABINE + CYTARABINE |